{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:23:10Z","timestamp":1786616590971,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejca.2023.113434","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T11:40:07Z","timestamp":1700048407000},"page":"113434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort"],"prefix":"10.1016","volume":"196","author":[{"given":"Eric","family":"Jonasch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos P.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime R.","family":"Merchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dror Michaelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard J.","family":"Appleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo F.","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2023.113434_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejca.2023.113434_bib2","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.113434_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2023.113434_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"14","key":"10.1016\/j.ejca.2023.113434_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2023.113434_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","article-title":"The cancer genome atlas of renal cell carcinoma: findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113434_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"Kondo","year":"2003","journal-title":"PLOS Biol"},{"key":"10.1016\/j.ejca.2023.113434_bib8","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2\u2013VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejca.2023.113434_bib9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.eururo.2015.11.029","article-title":"Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel-Lindau gene mutation status","volume":"70","author":"Messai","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2023.113434_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.critrevonc.2017.01.013","article-title":"Targeting HIF-2 alpha in clear cell renal cell carcinoma: a promising therapeutic strategy","volume":"111","author":"Martinez-Saez","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.ejca.2023.113434_bib11","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.drudis.2019.09.008","article-title":"Allosteric inhibition of HIF-2alpha as a novel therapy for clear cell renal cell carcinoma","volume":"24","author":"Yu","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ejca.2023.113434_bib12","unstructured":"Welireg\u2122 (belzutifan) tablets, for oral use. Merck Sharp & Dohme LLC, Rahway, NJ, USA; 2023."},{"issue":"5","key":"10.1016\/j.ejca.2023.113434_bib13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ejca.2023.113434_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113434_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.semnephrol.2019.12.009","article-title":"Immune checkpoint inhibitors in the treatment of renal cell carcinoma","volume":"40","author":"Parikh","year":"2020","journal-title":"Semin Nephrol"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2023.113434_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1634\/theoncologist.2011-S2-32","article-title":"Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies","volume":"16","author":"Ravaud","year":"2011","journal-title":"Oncologist"},{"issue":"22","key":"10.1016\/j.ejca.2023.113434_bib17","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2023.113434_bib18","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1200\/JCO.2022.40.16_suppl.4546","article-title":"LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2\u03b1 inhibitor (HIF-2\u03b1), for von Hippel-Lindau (VHL) disease: update with more than two years of follow-up data","volume":"40","author":"Jonasch","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2023.113434_bib19","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/j.annonc.2021.08.052","article-title":"Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)","volume":"32","author":"McDermott","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113434_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2023.113434_bib21","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"10","author":"Hofmann","year":"2020","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:56Z","timestamp":1760733776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923007360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":21,"alternative-id":["S0959804923007360"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113434","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113434"}}